Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Terfenadine
Drug ID BADD_D02637
Description In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.
Indications and Usage For the treatment of allergic rhinitis, hay fever, and allergic skin disorders.
Marketing Status approved; withdrawn
ATC Code R06AX12
DrugBank ID DB00342
KEGG ID D00521
MeSH ID D016593
PubChem ID 5405
TTD Drug ID D08SOF
NDC Product Code Not Available
UNII 7BA5G9Y06Q
Synonyms Terfenadine | Terfenidine | alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperdinebutanol | Ternadin | Balkis Saft Spezial | Rapidal | RMI-9918 | RMI 9918 | RMI9918 | Seldane | Triludan | Teldane | Terfedura | Terfemundin | Terfenadin AL | Terfenadin Heumann | Terfenadin Stada | Terfenadin Von Ct | Terfenadin-Ratiopharm | Terfenadin Ratiopharm | Cyater | Hisfedin
Chemical Information
Molecular Formula C32H41NO2
CAS Registry Number 50679-08-8
SMILES CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agitation19.06.02.001; 17.02.05.012--
Anxiety19.06.02.002--
Asthenia08.01.01.001--Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Cold sweat23.02.03.002; 08.01.03.024--Not Available
Depression19.15.01.001--
Diarrhoea07.02.01.001--
Disorientation19.13.01.002; 17.02.05.015--Not Available
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug interaction08.06.03.001--Not Available
Dyspepsia07.01.02.001--
Epistaxis24.07.01.005; 22.04.03.001--
Erythema23.03.06.001--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Fatigue08.01.01.002--
Flushing23.06.05.003; 24.03.01.002; 08.01.03.025--
Hallucination19.10.04.003--
Headache17.14.01.001--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Insomnia19.02.01.002; 17.15.03.002--
Jaundice01.06.04.004; 23.03.03.030; 09.01.01.004--Not Available
Loss of consciousness17.02.04.004--Not Available
Malaise08.01.01.003--
Nausea07.01.07.001--
Palpitations02.11.04.012--
Paraesthesia23.03.03.094; 17.02.06.005--
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene